Question: What rices have been found to inhibit the progression of atherosclerotic plaque development?
About the article "Rice", section "Nutrients and the nutritional importance of rice".

Candidate passages:
Lipoprotein Associated Phospholipase A2 has been identified and verified in multiple human trials as an enzymatic activity which is an independent predictor of atherosclerotic disease progression and events in humans, including coronary heart disease, because it promotes oxidation of lipoproteins and certain fatty acids.
It is available to physicians and patients as a blood test from multiple clinical labs, including LipoScience, and is commonly promoted as the PLAC test.
It does not actually measure or reflect the amount of atherosclerotic plaque present, only one factor affecting progression of existing atherosclerotic plaques.
As of 2009, there is no treatment for elevated levels of this enzymatic activity, though inhibitors are in development and clinical trials.
Thus currently it is only a marker which can serve as an indicator for more aggressive treatment of those physiologic behaviors which can be changed to slow/halt progression of atherosclerosis. 
Through cerebral angiography, the sign has been demonstrated to correspond to embolic or atherosclerotic occlusion of an artery.
Specifically, the hyperdensity is thought to be due to calcification or hemorrhage associated with an atherosclerotic plaque. 
The protein encoded by this gene is a metastasis suppressor of melanomas and breast cancers without affecting tumorigenicity.
The encoded protein may function to inhibit chemotaxis and invasion, attenuating metastasis in malignant melanomas.
It is found in atherosclerotic plaques of the coronary arteries. 
Whether the toxicity of oral intake of vitamin D is due to it being unnatural is not known.
However, evidence suggests that dietary vitamin D may be carried by lipoprotein particles into cells of the artery wall and atherosclerotic plaque, where it may be converted to active form by monocyte-macrophages.
This raises questions regarding the effects of vitamin D intake on atherosclerotic calcification and cardiovascular risk as it may be causing vascular calcification.
Calcifediol is implicated in the etiology of atherosclerosis, especially in non-Caucasians.
The levels of the active form of vitamin D, calcitriol, are inversely correlated with coronary calcification Moreover, the active vitamin D analog, alfacalcidol, seems to protect patients from developing vascular calcification.
Serum vitamin D has been found to correlate with calcified atherosclerotic plaque in African Americans as they have higher active serum vitamin D levels compared to Euro-Americans.
Higher levels of calcidiol positively correlate with aorta and carotid calcified atherosclerotic plaque in African Americans but not with coronary plaque, whereas individuals of European descent have an opposite, negative association.
There are racial differences in the association of coronary calcified plaque in that there is less calcified atherosclerotic plaque in the coronary arteries of African-Americans than in whites.
A case control study on a population in southern India found that more than 50% of patients with ischaemic heart disease had serum levels of vitamin D higher than 222.5 nmol/L, but the study did not evaluate causation.
Among descent groups with heavy sun exposure during their evolution, taking supplemental vitamin D to attain the 25(OH)D level associated with optimal health in studies done with mainly European populations may have deleterious outcomes.
Despite abundant sunshine in India, vitamin D status in Indians are low and suggests a public health need to fortify Indian foods with vitamin D. However the levels found in India are consistent with many other studies of tropical populations which have found that even an extreme amount of sun exposure, does not raise 25(OH)D levels to the levels typically found in Europeans.
Recommendations stemming for a single standard for optimal serum 25(OH)D concentrations ignores the differing genetically mediated determinates of serum 25(OH)D and may result in ethnic minorities in Western countries having the results of studies done with subjects not representative of ethnic diversity applied to them.
Vitamin D levels vary for genetically mediated reasons as well as environmental ones. 
Alvocidib (INN; also known as Flavopiridol or HMR-1275) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia, by Sanofi.
It has been studied also for the treatment of arthritis and atherosclerotic plaque formation The target of Flavopiridol is the positive transcription elongation factor P-TEFb.